TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01906268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification Treatment (ABMT) - Active
Description: The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (\< or \>) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.~Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Attentional Bias Modification Treatment - Placebo
Description: The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.~Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)
Study: NCT03478670

Intervention type: GENETIC
Intervention: Strimvelis
Description: Strimvelis is a CD34+ cell enriched dispersion of human autologous bone marrow derived hematopoietic stem/progenitor cells transduced with a retroviral vector containing the human ADA gene. It will be administered as an intravenous infusion once only.~This is an observational registry that includes all patients who have previously received Strimvelis™ or GSK2696273.
Study: NCT03250143

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine vs azathioprine
Description: Group A cyclosporine 3mg/kg/day and group B azathioprine 1mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine vs azathioprine
Description: Group A cyclosporine 3mg/kg/day and group B azathioprine 1mg/kg/day
Study: NCT02392988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture treatment
Description: acupuncture treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo Comparator
Study: NCT01938261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.45 % saline solution
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.45 % saline solution
Description: Placebo
Study: NCT01763866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally once a day
Study: NCT00592410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human regular insulin
Description: administration of a primed continuous infusion of human regular insulin at a rate of 2.0 mU/kg/min while maintaining the plasma glucose level at 100 mg/dl via adjusting a variable infusion of 50% dextrose (i.e., a hyperinsulinemic euglycemic blood glucose clamp); duration of 3 hours; performed concomitantly with amino acid supplementation
Study: NCT02725294

Intervention type: OTHER
Intervention: This is an observational study without an intervention
Description: Not applicable. This is an observational study without an intervention.
Study: NCT01763866

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally once a day
Study: NCT06715930

Intervention type: PROCEDURE
Intervention: Interventional treatment
Description: The procedure was performed via the traditional transfemoral arterial approach, under general anesthesia and complete heparin anticoagulation. PEDs were introduced using Marksman or Phenom-27 microcatheters (Medtronic, Irvine, USA), while coils were introduced via Echelon-10 microcatheters (Medtronic, Dublin, Ireland). An appropriate working projection was used to generate three-dimensional rotational angiography. Un-subtracted images were used to verify whether PED was completely deployed and attached to the parent artery. Wall apposition was enhanced using balloon angioplasty if post-deployment imaging indicated inadequate apposition. Overlapping devices were used when a single PED was not enough to cover the aneurysm neck and reconstruct blood flow. Neurointerventionalists with more than 15 years of experience conducted all endovascular procedures. The same dual-antiplatelet therapy was used for 6 months post-procedure, followed by aspirin monotherapy for a minimum of 12 months.

Intervention type: PROCEDURE
Intervention: Interventional treatment
Description: The procedure was performed via the traditional transfemoral arterial approach, under general anesthesia and complete heparin anticoagulation. PEDs were introduced using Marksman or Phenom-27 microcatheters (Medtronic, Irvine, USA), while coils were introduced via Echelon-10 microcatheters (Medtronic, Dublin, Ireland). An appropriate working projection was used to generate three-dimensional rotational angiography. Un-subtracted images were used to verify whether PED was completely deployed and attached to the parent artery. Wall apposition was enhanced using balloon angioplasty if post-deployment imaging indicated inadequate apposition. Overlapping devices were used when a single PED was not enough to cover the aneurysm neck and reconstruct blood flow. Neurointerventionalists with more than 15 years of experience conducted all endovascular procedures. The same dual-antiplatelet therapy was used for 6 months post-procedure, followed by aspirin monotherapy for a minimum of 12 months.
Study: NCT01763866

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin
Description: Administered orally once a day
Study: NCT00025363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study: NCT01336816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ariva Silver Wintergreen
Description: Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Wintergreen
Description: Placebo Wintergreen lozenge containing no tobacco, nicotine, or silver salt, administered orally as a single dose.
Study: NCT04486690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketofol (propofol to ketamine ratio 1:1)
Description: * Ketofol 25-150 mic/kg/min with propofol to ketamine ratio 1:1.~* Fentanyl infusion, 1-2 mcg/kg/h.~* Atracurium infusion, 3-12 mic/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Propofol infusion, 25-150 mcg/kg/min.~* Fentanyl infusion, 1-2 mcg/kg/h.~* Atracurium infusion, 3-12 mic/kg/min.
Study: NCT01852643

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spreader graft
Description: Spreader graft technique is performed by a group of expert surgeons.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral crural overlay
Description: Lateral crural overlay technique is performed by a group of expert surgeons.
Study: NCT03827239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity/Moderate Exercise
Description: 3-hour sedentary period with 3 minute activity breaks of moderate exercise every 30 minutes
Study: NCT02751944

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NEM
Description: Dietary supplement for the support of joint health.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04584047

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cell-based non-invasive prenatal testing
Description: Blood sampling.
Study: NCT02311803

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preservation of Denonvilliers Fascia
Description: In this group, patients accepte L-PANP surgery without excision of Denonvilliers Fascia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Excision of Denonvilliers Fascia
Description: In this group, patients accepte L-PANP surgery with excision of Denonvilliers Fascia
Study: NCT00894777

Intervention type: OTHER
Intervention: Clinical record review
Study: NCT04574856

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose-Intensified Radiotherapy
Description: Adaptive, dose-intensified radiotherapy targeting an advanced imaging signature, with a target, nominal radiotherapy dose of 80 Gy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide chemotherapy (75 mg/m2 daily for 6 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant temozolomide
Description: Adjuvant temozolomide will be delivered at 150-200 mg/m2 days 1-5 every 28 days for 6 cycles, with additional cycles delivered at the discretion of the investigator.
Study: NCT00696124

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202 2 mg
Description: 2 mg intramuscular injection with the first half of the total dose given on Day 1 and the second half on Day 15

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202 4 mg
Description: 4 mg intramuscular injection, with half of the total dose given on Day 1 and the second half given on Day 15

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202 8 mg
Description: 8 mg intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202 16 mg
Description: 16 mg dose intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
Study: NCT03217266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navtemadlin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navtemadlin
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgery
Study: NCT04122378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: The acupuncture will be provided by the licensed acupuncturist using standard methods.
Study: NCT00503984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Intravenous infusion over 30 minutes Days 1 - 5 of each 3 weekly cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Intravenous infusion over 30 minutes Days 1 - 5 of each 3 weekly cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous infusion over 1 hour on day 6 of each 3 weekly cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous infusion over 1 hour on day 6 of each 3 weekly cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Patient will receive prednisone 5mg twice a day from Day 1 to 21 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Patient will receive prednisone 5mg twice a day from Day 1 to 21 of each cycle.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GADD45α methylation and expression analysis
Description: Peripheral blood samples from patients will be collected as described in section 8.1 (total of 4 blood samples). DNA will be isolated from serum, bisulfite treated and evaluated for methylation by bisulfite genomic sequencing.~Patients with accessible prostate tissue or metastases will undergo biopsy prior to treatment if they consent to do so.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Growth factor support.Granulocyte-colony stimulating factor (G-CSF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Growth factor support.Granulocyte-colony stimulating factor (G-CSF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Growth factor support. Granulocyte-colony stimulating factor (G-CSF)
Study: NCT01763866

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin
Description: Administered orally once a day
Study: NCT00025363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirapazamine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirapazamine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study: NCT02934763

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: propranolol iv by target controlled infusion, to achieve specific plasmatic concentration goals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: propranolol iv by target controlled infusion, to achieve specific plasmatic concentration goals

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline as placebo
Study: NCT01769339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miconazole plus Hydrocortisone
Description: Participants will apply miconazole plus hydrocortisone cream topically to the lesion twice daily up to Day 14 by rubbing gently until it has been completely penetrated into the affected vulvar (the tissues around the opening to the vagina) area and the treatment should be continued without interruption. Participants will be assessed for signs and symptoms of vulvar candidiasis at Day 14. Medication will be continued till Day 28, if signs and symptoms of vulvar candidiasis are not cured clinically on Day 14.
Study: NCT00969319

Intervention type: BIOLOGICAL
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Patients under daily life treatment receiving Kogenate according to local drug information.
Study: NCT02722148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy
Description: A novel assay developed by the investigator to diagnose food allergens. Results from the assay are used to guide food elimination therapy for the treatment of Eosinophilic Esophagitis (EoE).
Study: NCT04407078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex Injectable Product
Description: Sugammadex of 2 mg/kg is injected.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neostigmine Injectable Product
Description: Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.
Study: NCT00025363

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC
Study: NCT01236560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study: NCT02268266

Intervention type: DEVICE
Group type: OTHER
Intervention: Erigo
Description: The control of cardiovascular parameters within suitable ranges for healthy and neurological patients using verticalization, leg mobilization and electrical stimulation
Study: NCT04461119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evenamide
Description: oral capsules for 4 weeks of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evenamide
Description: oral capsules for 4 weeks of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsules for 4 weeks of treatment
Study: NCT00503984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Growth factor support. Granulocyte-colony stimulating factor (G-CSF)
Study: NCT02670902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention-Residential (CTI-R)
Description: CTI-R is a 9-month, time-limited intervention that aims to produce an enduring impact by effectively linking individuals to both professional services (substance abuse and health and mental health providers) and social supports (e.g., family and friends) and by providing emotional and practical support. Participants in the CTI-R condition will also receive usual discharge services from the residential substance abuse treatment program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Discharge Services-Residential
Description: The enhanced usual discharge condition encompasses the regular discharge services offered at the residential treatment program plus enhanced transition services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Discharge Services-Residential
Description: The enhanced usual discharge condition encompasses the regular discharge services offered at the residential treatment program plus enhanced transition services.
Study: NCT01783444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine, tablets for oral use, 1250 mg/m² twice daily for 2 weeks followed by one week rest (3-week-cycle) (locally supplied)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Exemestane, tablets for oral use, 25 mg per day in (locally supplied)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus, 5 mg tablets for oral use, 10 mg (2 x 5 mg) per day (centrally supplied)
Study: NCT00025363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01763866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: Administered orally once a day
Study: NCT04780958

Intervention type: OTHER
Group type: OTHER
Intervention: Serum retinol and RBP levels were determined by enzyme-linked immunosorbent assay.
Description: Umbilical cord blood was drawn at birth in all babies included in the study by experienced individuals using a vacutainer. Approximately 6 ml of venous blood was also drawn from the antecubital region of the mothers immediately after the birth in a biochemistry tube.In the serum samples, the retinol levels were analyzed using ELISA kits from the Bioassay Technology Laboratory ( E1548 Hu Jiaxing, Zhejiang, China), RBP levels were analyzed using ELISA kits of Elabscience (E-EL-H1581 Texas USA) following the standard protocol suggested by the manufacturer at the Dynex automated ELISA reading device (Dynex Technologies Headquarters, Chantilly, USA)
Study: NCT03363217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Daily administration of oral trametinib at a unique dose of 0.025 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Daily administration of oral trametinib at a unique dose of 0.025 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Daily administration of oral trametinib at a unique dose of 0.025 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Daily administration of oral trametinib at a unique dose of 0.025 mg/kg.
Study: NCT04173052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Testis' shocker
Description: The device gives electrical shock ranged (1-5) milliAmpere designed to fit the testis shape for the males.
Study: NCT02397603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine bupivacaine
Description: perineural dexmedetomidine as an adjuvant to bupivacaine induced thoracic paravertebral block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine saline
Description: perineural bupivacaine saline mixture in the thoracic paravertebral catheter
Study: NCT04196205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR-T
Description: 1 - 2×10\^6 Anti-CD19 CAR-T cells/kg body weigh